Arachnoiditis Market: The increasing number of surgical procedures along with a growing geriatric population is projected to boost the market growth at a healthy CAGR during the forecast period from 2022 to 2030

Pune, India, October 2022/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global Arachnoiditis market.

Market Highlights

The Arachnoiditis Market is expected to reach USD 2.30 Billion by 2030 at 3.50% CAGR during the forecast period 2022 -2030.

Arachnoiditis is a rare disorder related to the spine which is caused by damage to the arachnoid layer. According to the scientists and researchers, arachnoiditis is not curable, but the pain caused by the disease can be controlled by using combined therapies. The growth of the global arachnoiditis market is depended on increasing geriatric population along with rising number of surgical procedures, increasing healthcare expenditure, and favorable reimbursement policies. According to the US Centers for Medicare & Medicaid Services, the US has spent USD 3.3 trillion on healthcare in the year 2016 which is approximately USD 10,348 per person.

The high costs associated with the treatment of arachnoiditis, stringent regulatory environment for product approval, and a dearth of experts are likely to hinder the market growth during the forecast period.

Regional Analysis

The market in the Americas is expected to dominate the global arachnoiditis market during the forecast period due to the rising number of surgeries, technological advancement along with high adoption rate, and favorable regulatory and government authorities. The European market is expected to hold the second position in global arachnoiditis market, factors responsible for the growth of the market in the European region are government support and increasing spending on healthcare, growing geriatric population and increasing research and development activities in the region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing market during the forecast period owing to the constantly increasing population, increasing number of chronic diseases like tuberculosis and acute back pain due to the changing lifestyle. The market in the Middle East & Africa is likely to account for the smallest share of the global arachnoiditis market. The market growth in this region can be attributed to the increasing development and rising investment in the healthcare sector.

The American region is likely to hold the maximum market share and the US will dominate the country level market.

Explore In-depth Details: Arachnoiditis Market Research Report

Segmentation

The global arachnoiditis market has been classified on the basis of type, cause, diagnosis, treatment, and end-user.

The market, by type, has been classified as adhesive arachnoiditis, arachnoiditis ossificans, arachnoiditis ossificans, cerebral arachnoiditis, hereditary arachnoiditis, neoplastic arachnoiditis, and optochiasmatic arachnoiditis.

On the basis of cause, the market has been segmented into trauma/surgery induced, chemically induced, and infection-induced. The trauma/surgery induced segment is divided into spinal surgery, lumbar puncture, spinal stenosis, and others. The chemically induced segment is further divided into myelograms and epidural steroid injection. The infection-induced segment is classified into viral and fungal meningitis, and tuberculosis.

Diagnosis segment has been classified into CAT scan (computerized axial tomography), MRI (magnetic resonance imaging), and Electromyogram (EMG).

Based on treatment, the market has been divided into Physical therapy, Pain medications, Nerve stimulation, and psychological support. The physical therapy segment is further divided into hydrotherapy, massage, and hot/cold therapy. lidocaine intravenous (IV) infusion, ketamine IV infusions, and naltrexone are part of pain medications. Nerve stimulation segment is divided into spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS).

The market on the basis of end-user has been segmented on the basis of hospital and clinics, pharmacies, diagnostic centers, and others.

The pain medication segment will register the maximum market share during the forecast period and nerve stimulation treatment segment will be the fastest growing segment.

Key Players

Some of the key players in the global arachnoiditis market are Bristol-Myers Squibb Company, Abbott, Pfizer Inc., Baxter, B. Braun Melsungen AG, SR Pharma, AstraZeneca, DuPont, Sandoz International GmbH, Takeda Pharmaceutical Company Limited, and Novartis AG.